SG Americas Securities LLC bought a new stake in InnovAge Holding Corp. (OTCMKTS:INNV – Get Rating) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 87,301 shares of the company’s stock, valued at approximately $437,000. SG Americas Securities LLC owned approximately 0.06% of InnovAge at the end of the most recent quarter.
Several other institutional investors also recently made changes to their positions in the stock. Royal Bank of Canada lifted its position in shares of InnovAge by 1,644.4% in the 2nd quarter. Royal Bank of Canada now owns 1,256 shares of the company’s stock worth $27,000 after purchasing an additional 1,184 shares during the period. Morgan Stanley acquired a new position in shares of InnovAge during the 1st quarter valued at $64,000. Allspring Global Investments Holdings LLC acquired a new position in shares of InnovAge during the 4th quarter valued at $37,000. Jane Street Group LLC acquired a new position in shares of InnovAge during the 3rd quarter valued at $68,000. Finally, UBS Group AG lifted its position in shares of InnovAge by 5,126.1% during the 3rd quarter. UBS Group AG now owns 11,027 shares of the company’s stock valued at $73,000 after acquiring an additional 10,816 shares during the period. 10.92% of the stock is currently owned by institutional investors.
OTCMKTS INNV opened at $5.13 on Friday. InnovAge Holding Corp. has a 1 year low of $3.46 and a 1 year high of $23.60. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.98 and a quick ratio of 2.98. The firm has a market cap of $695.20 million, a price-to-earnings ratio of 51.31 and a beta of 1.51. The company has a fifty day moving average price of $5.69 and a 200-day moving average price of $5.99.
A number of research analysts recently issued reports on INNV shares. Piper Sandler dropped their target price on shares of InnovAge from $5.00 to $3.90 in a research report on Wednesday. Zacks Investment Research downgraded shares of InnovAge from a “hold” rating to a “sell” rating in a report on Friday, April 22nd. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $10.91.
InnovAge Profile (Get Rating)
InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in their homes and communities. It manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. The company offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management.
- Get a free copy of the StockNews.com research report on InnovAge (INNV)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for InnovAge Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InnovAge and related companies with MarketBeat.com's FREE daily email newsletter.